Peter J.M. Valk
About
Peter J.M. Valk is a scholar working on Hematology, Molecular Biology and Genetics.
According to data from OpenAlex, Peter J.M. Valk has authored 190 papers receiving a total of 10.0k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Hematology, 102 papers in Molecular Biology and 50 papers in Genetics. Recurrent topics in Peter J.M. Valk's work include Acute Myeloid Leukemia Research (131 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (33 papers) and Chronic Myeloid Leukemia Treatments (29 papers). Peter J.M. Valk is often cited by papers focused on Acute Myeloid Leukemia Research (131 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (33 papers) and Chronic Myeloid Leukemia Treatments (29 papers). Peter J.M. Valk collaborates with scholars based in Netherlands, United States and Germany. Peter J.M. Valk's co-authors include Bob Löwenberg, Ruud Delwel, Claudia Erpelinck-Verschueren, H. Berna Beverloo, Roel G.W. Verhaak, Bas J. Wouters, Mathijs A. Sanders, Sanne Lugthart, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani and Peter J. van der Spek and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Nucleic Acids Research.
In The Last Decade
Peter J.M. Valk
182 papers receiving 9.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Peter J.M. Valk Netherlands | 49 | 6.2k | 5.9k | 2.1k | 1.6k | 1.2k | 190 | 10.0k | ||
| Ruud Delwel Netherlands | 50 | 5.3k 0.9× | 5.4k 0.9× | 1.4k 0.7× | 1.1k 0.7× | 1.1k 0.9× | 163 | 9.1k | ||
| Matthew J. Walter United States | 29 | 2.6k 0.4× | 4.5k 0.8× | 1.1k 0.5× | 2.3k 1.4× | 330 0.3× | 107 | 7.6k | ||
| Mark J. Routbort United States | 41 | 1.3k 0.2× | 1.6k 0.3× | 1.0k 0.5× | 1.8k 1.1× | 292 0.2× | 162 | 5.4k | ||
| Roel G.W. Verhaak United States | 42 | 1.4k 0.2× | 8.0k 1.4× | 1.9k 0.9× | 5.3k 3.3× | 318 0.3× | 95 | 13.5k | ||
| Michael G. Kharas United States | 36 | 1.1k 0.2× | 4.2k 0.7× | 869 0.4× | 1.6k 1.0× | 151 0.1× | 77 | 5.6k | ||
| Thomas Hielscher Germany | 39 | 1.3k 0.2× | 3.3k 0.6× | 1.5k 0.7× | 1.1k 0.7× | 93 0.1× | 181 | 5.9k | ||
| Joshua F. McMichael United States | 11 | 1.0k 0.2× | 3.3k 0.6× | 603 0.3× | 2.0k 1.2× | 136 0.1× | 16 | 5.8k | ||
| Xabier Agirre Spain | 39 | 852 0.1× | 3.9k 0.7× | 424 0.2× | 2.2k 1.4× | 312 0.3× | 110 | 4.9k | ||
| H. Jeffrey Lawrence United States | 33 | 1.3k 0.2× | 3.4k 0.6× | 271 0.1× | 495 0.3× | 222 0.2× | 57 | 4.8k | ||
| Neill A. Giese United States | 26 | 1.0k 0.2× | 2.2k 0.4× | 1.8k 0.8× | 484 0.3× | 151 0.1× | 43 | 4.5k |
Countries citing papers authored by Peter J.M. Valk
Since
Specialization
Citations
This map shows the geographic impact of Peter J.M. Valk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter J.M. Valk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter J.M. Valk more than expected).
Fields of papers citing papers by Peter J.M. Valk
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Peter J.M. Valk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter J.M. Valk. The network helps show where Peter J.M. Valk may publish in the future.
Co-authorship network of co-authors of Peter J.M. Valk
This figure shows the co-authorship network connecting the top 25 collaborators of Peter J.M. Valk. A scholar is included among the top collaborators of Peter J.M. Valk based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter J.M. Valk. Peter J.M. Valk is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Bergevoet, Saskia M., Pascal W.T.C. Jansen, Anja Krippner‐Heidenreich, et al.. (2024). HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia. Leukemia. 39(2). 371–380.
2.
Daele, Paul Van, et al.. (2024). Long‐term genetic and clinical remissions after cessation of azacitidine treatment in patients with VEXAS syndrome. HemaSphere. 8(8). e129–e129.
3.
Pereira‐Martins, Diego A., Isabel Weinhäuser, Juan Luiz Coelho‐Silva, et al.. (2024). A 4‐gene prognostic index for enhancing acute myeloid leukaemia survival prediction. British Journal of Haematology. 204(6). 2287–2300.
4.
Schittenhelm, Marcus M., Gunnar Blumenstock, Balázs Győrffy, et al.. (2024). High iASPP (PPP1R13L) expression is an independent predictor of adverse clinical outcome in acute myeloid leukemia (AML). Cell Death and Disease. 15(11). 869–869.
5.
Ravandi, Farhad, Jacqueline Cloos, Francesco Buccisano, et al.. (2023). Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower‐intensity therapy: Roadmap from an ELN‐DAVID expert panel. American Journal of Hematology. 98(12). 1847–1855.
6.
Grob, Tim, Adil S. A. Al Hinai, Mathijs A. Sanders, et al.. (2022). Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 139(15). 2347–2354.
7.
Werf, Inge van der, Anna Wojtuszkiewicz, Manja Meggendorfer, et al.. (2021). Splicing factor gene mutations in acute myeloid leukemia offer additive value if incorporated in current risk classification. Blood Advances. 5(17). 3254–3265.
8.
Lundberg, Pontus, Alexandar Tzankov, Martina Kleber, et al.. (2020). Secondary CNL after SAA reveals insights in leukemic transformation of bone marrow failure syndromes. Blood Advances. 4(21). 5540–5546.
9.
Kemps, Paul G., Konnie M. Hebeda, Steven T. Pals, et al.. (2020). Spectrum of histiocytic neoplasms associated with diverse haematological malignancies bearing the same oncogenic mutation. The Journal of Pathology Clinical Research. 7(1). 10–26.
10.
Thielen, Noortje, Jeroen J. W. M. Janssen, Mels Hoogendoorn, et al.. (2017). Omitting cytogenetic assessment from routine treatment response monitoring in chronic myeloid leukemia is safe. European Journal Of Haematology. 100(4). 367–371.
11.
Dzneladze, Irakli, John F. Woolley, Meong Hi Son, et al.. (2015). INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. Leukemia. 29(7). 1485–1495.
12.
Vliet, Martin H. van, Jaap Brand, Henk E. Viëtor, et al.. (2013). Detection of CEBPA Double Mutants in Acute Myeloid Leukemia Using a Custom Gene Expression Array. Genetic Testing and Molecular Biomarkers. 17(5). 395–400.
13.
Vliet, Martin H. van, Erik Simons, Lars Bullinger, et al.. (2013). Detection of Mutant NPM1 mRNA in Acute Myeloid Leukemia Using Custom Gene Expression Arrays. Genetic Testing and Molecular Biomarkers. 17(4). 295–300.
14.
Geertsma-Kleinekoort, W. M. C., et al.. (2013). Addition of β-Mercaptoethanol Is a Prerequisite for High-Quality RNA Isolation Using QIAsymphony Technology as Demonstrated by Detection of Molecular Aberrations in Hematologic Malignancies. Genetic Testing and Molecular Biomarkers. 17(6). 475–480.
15.
Thielen, Noortje, Bronno van der Holt, Jan J. Cornelissen, et al.. (2013). Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON). European Journal of Cancer. 49(15). 3242–3246.
16.
Kvinlaug, Brynn T., Lars Bullinger, Mukundhan Ramaswami, et al.. (2011). Common and Overlapping Oncogenic Pathways Contribute to the Evolution of Acute Myeloid Leukemias. Cancer Research. 71(12). 4117–4129.
17.
Jonge, Hendrik J.M. de, Peter J.M. Valk, Nic J.G.M. Veeger, et al.. (2010). High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood. 116(10). 1747–1754.
18.
Taskesen, Erdogan, Lars Bullinger, Andrea Corbacioglu, et al.. (2010). Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further evidence for CEBPA double mutant AML as a distinctive disease entity. Blood. 117(8). 2469–2475.
19.
Erkeland, Stefan J., Roel G.W. Verhaak, Peter J.M. Valk, et al.. (2006). Significance of Murine Retroviral Mutagenesis for Identification of Disease Genes in Human Acute Myeloid Leukemia. Cancer Research. 66(2). 622–626.
20.
Valk, Peter J.M., et al.. (2005). Evaluating the Effectiveness of TDM and Public Awareness Programs for the US 101 Highway Reconstruction Project in San Luis Obispo, California. 13(2).
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ruud Delwel Breakdown of academic impact, for papers by Matthew J. Walter Breakdown of academic impact, for papers by Mark J. Routbort Breakdown of academic impact, for papers by Roel G.W. Verhaak Breakdown of academic impact, for papers by Michael G. Kharas Breakdown of academic impact, for papers by Thomas Hielscher Breakdown of academic impact, for papers by Joshua F. McMichael Breakdown of academic impact, for papers by Xabier Agirre Breakdown of academic impact, for papers by H. Jeffrey Lawrence Breakdown of academic impact, for papers by Neill A. Giese